Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to determine whether adding an educational intervention, in the form of a decision board, which outlines the risks and benefits of treatment options for DCIS, at the time of the first surgical consultation will improve decision making for women with DCIS.


Clinical Trial Description

- The decision board explains the risks and benefits of mastectomy, excision and radiation, excision, radiation, and tamoxifen, excision alone, and excision without radiation and tamoxifen for women with DCIS.

- Patients will receive a decision board to take home for review. Two fifteen-minute telephone interviews will be conducted, one approximately one week after enrollment and one 2 months after enrollment.

- In the phone interviews, patients will asked to complete a brief survey. This survey will ask abou DCIS in general, the patient's treatment decisions, their feelings, as well as their experience with the decision board.

- This study will take about 2 months. ;


Study Design

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label


Related Conditions & MeSH terms


NCT number NCT00148655
Study type Interventional
Source Dana-Farber Cancer Institute
Contact
Status Completed
Phase N/A
Start date May 2003
Completion date August 2006

See also
  Status Clinical Trial Phase
Completed NCT00256217 - Chemoprevention Trial - Anastrozole in Ductal Carcinoma In Situ (DCIS) in Postmenopausal Women Phase 2
Completed NCT03931928 - Genotype and Phenotype Guided Supplementation of TAMoxifen Standard Therapy With ENDOXifen in Breast Cancer Patients Phase 2
Terminated NCT03535506 - Preoperative Palbociclib in Patients With DCIS of the Breast That Are Candidates for Surgery Phase 2
Recruiting NCT04797299 - Prospective Evaluation of Breast-Conserving Surgery Alone in Low-Risk Ductal Carcinoma in Situ (DCIS)
Completed NCT02637024 - Trial of Radiation Fractionation Schedules for Once-a-Day Accelerated Partial Breast Irradiation Phase 2
Suspended NCT03936478 - Real-Time MRI-Guided 3-Fraction Accelerated Partial Breast Irradiation in Early Breast Cancer Phase 2
Recruiting NCT03878342 - Radiotherapy Omission in Low Risk Ductal in Situ Carcinoma Breast N/A
Recruiting NCT03793829 - Neoadjuvant Multi-epitope HER2 Peptide Vaccine in Patients With HER2-expressing DCIS Phase 1/Phase 2
Active, not recruiting NCT04245150 - Assessing the Impact of the Microbiome on Breast Cancer Radiotherapy Toxicity
Recruiting NCT06388304 - THRIVE Study: Positive Affect Training for Endocrine Therapy Medication Adherence N/A
Not yet recruiting NCT06217458 - The Added Value of Contrast Enhanced Mammography to Standard Mammography in Assessing the Extent of DCIS N/A
Recruiting NCT04722692 - Delayed Sentinel Lymph Node Biopsy in Ductal Cancer in Situ Phase 3
Enrolling by invitation NCT05868252 - Molecular Analysis of the Sloane Project
Recruiting NCT05912569 - Delayed Selective Sentinel Node Biopsy for Patients Undergoing Mastectomy for DCIS N/A
Recruiting NCT04049214 - Perioperative Mindfulness Proposal N/A
Completed NCT02061332 - DC Vaccine for Patients With Ductal Carcinoma In Situ Phase 1/Phase 2
Recruiting NCT04916808 - The AUS-PREDICT Registry for DCIS Patients With DCISionRT Testing
Withdrawn NCT05436808 - Partial Chest Wall Radiation Therapy After Surgery for Lymph Node Negative Breast Cancer Early Phase 1
Recruiting NCT05900986 - LS301-IT in Partial Mastectomy and Sentinel Lymph Node Biopsy (SLNB) for DCIS or Stage I-II Primary Invasive Breast Cancer Phase 1/Phase 2
Suspended NCT03448926 - The PREDICT Registry for DCIS Patients With DCISionRT Testing